Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

23.500
+0.1500.64%
Volume:3.05M
Turnover:72.12M
Market Cap:20.49B
PE:68.67
High:24.100
Open:23.550
Low:23.350
Close:23.350
Loading ...

Billionaire Li Ka-shing’s Hutchmed in $608 mln health unit stake sales

Reuters
·
02 Jan

China-based Hutchmed to divest stake in health unit for $608 million

Reuters
·
02 Jan

Li Ka-Shing-Backed Hutchmed Sells Stake in Unit for $608 Million

Bloomberg
·
01 Jan

BRIEF-HUTCHMED Announces $608 Mln Divestment Of Non-Core Joint Venture

Reuters
·
01 Jan

HUTCHMED- Entered Two Agreements to Divest 45% Equity Interest in Shanghai Hutchison Pharmaceuticals to Gp Health Service Capital, Shanghai Pharmaceuticals Holding

THOMSON REUTERS
·
01 Jan

HUTCHMED (China) Ltd - Divestment Proceeds to Advance HUTCHMED's Pipeline and Core Innovative Medicines Business

THOMSON REUTERS
·
01 Jan

HUTCHMED Announces US$608 Million Divestment of Non-Core Joint Venture

THOMSON REUTERS
·
01 Jan

HUTCHMED (China) Ltd - HUTCHMED Expects to Record a Gain on Disposal of Approximately US$477 Mln Before Taxation

THOMSON REUTERS
·
01 Jan

Press Release: HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

Dow Jones
·
01 Jan

Daiwa Securities Initiates Coverage on HUTCHMED With Buy Rating, $23 Price Target

MT Newswires Live
·
19 Dec 2024

Hutchmed to Receive $10 Million Milestone Payment Through Takeda

MT Newswires Live
·
13 Dec 2024

BRIEF-Hutchmed China Ltd Will Receive $10 Mln Milestone Payment By Its Partner Takeda

Reuters
·
13 Dec 2024

HUTCHMED (China) Ltd: Will Receive $10 Mln Milestone Payment by Its Partner Takeda

THOMSON REUTERS
·
13 Dec 2024

HUTCHMED (China) to Receive $10 Million Milestone Payment From Takeda After First European Reimbursement for Fruzaqla

MT Newswires Live
·
13 Dec 2024

HUTCHMED to Receive Milestone Payment From Takeda Following First European Reimbursement for Fruzaqla® (Fruquintinib)

THOMSON REUTERS
·
13 Dec 2024

China Grants Hutchmed Breakthrough Designation for Non-Small Cell Lung Cancer Drug

MT Newswires Live
·
12 Dec 2024

HUTCHMED Secures Breakthrough Therapy Designation in China for Lung Cancer Drug Combination

MT Newswires Live
·
12 Dec 2024

BRIEF-Hutchmed (China) Says Breakthrough Therapy Designation For Orpathys And Tagrisso Combination

Reuters
·
12 Dec 2024

HUTCHMED Announces Breakthrough Therapy Designation in China for Orpathys® and Tagrisso® Combination in Certain Lung Cancer Patients After Disease Progression on Egfr Inhibitor Therapy

THOMSON REUTERS
·
12 Dec 2024

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

GlobeNewswire
·
12 Dec 2024